Telefon:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antikoerper-online.de

Programmed Cell Death 1 (PDCD1) (AA 25-167) (Active) protein (Fc Tag) Protein

PDCD1 Spezies: Human Wirt: HEK-293 Cells Recombinant >95 % as determined by SDS-PAGE. Active
Pubmed (6 Referenzen)
Produktnummer ABIN2181607
$363.00
Zzgl. Versandkosten $45.00
Lieferung in 2 bis 3 Werktagen
  • Target Alle PD-1 (PDCD1) Proteine anzeigen
    PD-1 (PDCD1)
    Protein-Typ
    Recombinant
    Biologische Aktivität
    Active
    Proteineigenschaft
    AA 25-167
    Spezies
    • 27
    • 11
    • 5
    • 4
    • 4
    • 1
    • 1
    Human
    Quelle
    • 34
    • 5
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    HEK-293 Cells
    Aufreinigungstag / Konjugat
    Dieses PD-1 Protein ist gelabelt mit Fc Tag.
    Sequenz
    AA 25-167
    Produktmerkmale
    This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 42.6 kDa. The protein migrates as 50-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
    Reinheit
    >95 % as determined by SDS-PAGE.
    Sterilität
    0.22 μm filtered
    Endotoxin-Niveau
    Less than 0.1 EU per μg by the LAL method.
  • Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Buffer
    PBS, pH 7.4
    Handhabung
    Please avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
  • Wang, Ni, Zhou, He, Gao, Wu, Wu, Wu, Qiu, Zhou, Chen, Pan, Huang, Li, Bian, Yang, Miao, Liu: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).

    Ganesan, Ahmed, Okoye, Arutyunova, Babu, Turnbull, Kundu, Shields, Agopsowicz, Xu, Tabana, Srivastava, Zhang, Moon, Belovodskiy, Hena, Kandadai, Hosseini, Hitt, Walker, Smylie, West, Siraki, Lemieux et al.: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." in: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).

    Zhao, Lee, Lin, Gassen, Xu, Huang, Xiao, Bonorino, Lu, Bui, Hui: "PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways." in: Immunity, Vol. 51, Issue 6, pp. 1059-1073.e9, (2019) (PubMed).

    Fromm, de Silva, Johannes, Patel, Hornblower, Schreiber: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." in: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).

    Mukundan, Guan, Singleton, Yang, Li, Parekkadan: "Artificial T Cell Mimetics to Combat Melanoma Tumor Growth." in: American journal of advanced drug delivery, Vol. 6, Issue 1, pp. 21-32, (2018) (PubMed).

    Lai, Huang, Wang, Lin, Yang: "A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects." in: Molecular therapy. Nucleic acids, Vol. 5, Issue 12, pp. e397, (2016) (PubMed).

  • Target
    PD-1 (PDCD1)
    Andere Bezeichnung
    PD-1 (PDCD1 Produkte)
    Synonyme
    CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, Ly101, Pdc1, programmed cell death 1, PDCD1, Pdcd1
    Hintergrund
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
    Molekulargewicht
    42.1 kDa
    NCBI Accession
    NP_005009
    Pathways
    Cancer Immune Checkpoints
Sie sind hier:
Kundenservice